About STipe Therapeutics
STipe Therapeutics is a company based in Aarhus (Denmark) founded in 2018. STipe Therapeutics has raised $23.41 million across 1 funding round from investors including Arix Bioscience, Novo Holdings and Wellington Partners Venture Capital. The company has 1 employees as of October 31, 2024. STipe Therapeutics operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
- Headquarter Aarhus, Denmark
- Employees 1 as on 31 Oct, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stipe Therapeutics Aps
-
Annual Revenue
Not available
-
Net Profit
-$1.17 M (USD)-51as on Dec 31, 2022
-
EBITDA
-$1.28 M (USD)-45as on Dec 31, 2022
-
Total Equity Funding
$23.41 M (USD)
in 1 rounds
-
Latest Funding Round
$23.41 M (USD), Series A
Sep 30, 2019
-
Investors
Arix Bioscience
& 3 more
-
Employee Count
1
as on Oct 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of STipe Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of STipe Therapeutics
STipe Therapeutics has successfully raised a total of $23.41M through 1 strategic funding round. The most recent funding activity was a Series A round of $23.41 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in STipe Therapeutics
STipe Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Arix Bioscience, Novo Holdings and Wellington Partners Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in biotech startups are made by Arix Bioscience.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Investments are made in early-stage healthcare startups.
|
Locked | Locked | Locked |
Investor details for STipe Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by STipe Therapeutics
Investment portfolio details for STipe Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - STipe Therapeutics
Detailed financials for STipe Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stipe Therapeutics Comparisons
Peer comparison for STipe Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of STipe Therapeutics
STipe Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
Detailed competitors of STipe Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stipe Therapeutics
Complete news archive for STipe Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about STipe Therapeutics
STipe Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
STipe Therapeutics is headquartered in Aarhus, Denmark.
STipe Therapeutics is a funded company, having raised a total of $23.41M across 1 funding round to date.
As of Oct 31, 2024, the latest employee count at STipe Therapeutics is 1.
STipe Therapeutics was founded in 2018 in Aarhus, Denmark, within the biotechnology sector. Therapeutics for cancer treatment are developed by the company, focusing on intracellular protein-protein interactions in the STING pathway. This approach is designed to enhance the innate immune systems detection of tumor-DNA, thereby aiding in the prevention of tumor cell growth. Operations center on drug development for oncology applications.
STipe Therapeutics's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
STipe Therapeutics has 4 investors. Key investors include Arix Bioscience, Novo Holdings, Wellington Partners Venture Capital, and Sunstone.